Daré Bioscience, Inc.
DARE · NASDAQ
9/30/2025 | 6/30/2025 | 3/31/2025 | 12/31/2024 | |
|---|---|---|---|---|
| Market Cap | $0 | $0 | $0 | $0 |
| - Cash | $0 | $0 | $0 | $0 |
| + Debt | $0 | $0 | $0 | $0 |
| Enterprise Value | $0 | $0 | $0 | $0 |
| Revenue | $0 | -$0 | $0 | -$0 |
| % Growth | 110.7% | -183.3% | 140% | – |
| Gross Profit | -$0 | -$0 | -$0 | -$0 |
| % Margin | -26,993.9% | 100% | -8,935.2% | 22,446% |
| EBITDA | -$0 | -$0 | -$0 | -$0 |
| % Margin | -120,987.2% | 15,906.5% | -17,394.9% | 8,455.7% |
| Net Income | -$0 | -$0 | -$0 | -$0 |
| % Margin | -157,505.1% | 18,970.7% | -17,219.1% | 8,651.5% |
| EPS Diluted | -0.279 | -0.45 | -0.5 | -0.65 |
| % Growth | 37.9% | 10% | 23.1% | – |
| Operating Cash Flow | -$0 | -$0 | -$0 | $0 |
| Capital Expenditures | -$0 | $0 | -$0 | -$0 |
| Free Cash Flow | -$0 | -$0 | -$0 | $0 |